Securities code: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) sz, 09989hk securities abbreviation: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Announcement No.: 2022011 Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) 2021 annual report summary I. important tips the summary of this annual report is from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development planning, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
Tips on non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of common shares or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors √ applicable □ not applicable whether to convert accumulation fund into share capital □ yes √ no
The company’s profit distribution plan for ordinary shares reviewed and approved by the board of directors is: take 1467296204 as the base, distribute cash dividends of 0.35 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 share (including tax), and do not use the accumulation fund to increase the share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) stock code Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) sz, 09989hk
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Qian Fengqi Zhang Wenchen
Office address: No. 21, Langshan Road, Songping mountain, Nanshan District, Shenzhen
Fax: 075586142889
Tel: 075526980311075526980311
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) was founded in Shenzhen in 1998. It is a leading multinational pharmaceutical enterprise with a + H dual financing platform. Its main business covers the investment, development and commercialization of heparin industrial chain, biomacromolecule cdmo and innovative drugs. It is committed to bringing high-quality safe and effective drugs and services to patients around the world and protecting their health. The main products and services include enoxaparin sodium preparation, heparin sodium and enoxaparin sodium API, as well as macromolecular drug cdmo services.
·Heparin industry chain
In the field of heparin industrial chain, the company’s main products include enoxaparin sodium preparation and heparin API, enoxaparin sodium API and heparin sodium injection.
Heparin is an anticoagulant drug extracted and processed from fresh healthy pig small intestine. It has many functions, such as anticoagulant, antithrombotic and so on. Heparin sodium API is mainly used to produce standard heparin preparation and low molecular weight heparin API, and then produce low molecular weight heparin preparation. The company has two major heparin sodium API production bases Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) and SPL. In addition to supplying part of heparin sodium API to Tiandao pharmaceutical, a wholly-owned subsidiary, heparin sodium API is mainly sold to foreign customers, including many world-famous multinational pharmaceutical enterprises. The main customers of enoxaparin sodium API are overseas enoxaparin sodium preparation manufacturers. Due to the company’s product quality advantages, major customers have maintained long-term and stable partnership with the company. Enoxaparin sodium preparation is a kind of low molecular weight heparin preparation, which is widely used in clinical practice. The main indications include: prevention of intravenous thromboembolic diseases (prevention of intravenous thrombosis), especially thrombosis related to orthopaedic or general surgery; Treatment of formed deep venous embolism with or without pulmonary embolism; Treat acute coronary syndrome and prevent thrombosis during hemodialysis and cardiopulmonary bypass. Since the company’s enoxaparin sodium preparation was approved by the European Drug Administration (EMA) through the centralized approval procedure (CP) in 2016, all five specifications on sale in 2020 took the lead in passing the consistency evaluation of the quality and efficacy of generic drugs in China. With excellent product quality and stable curative effect, the company’s cumulative export volume of enoxaparin sodium preparation ranks among the top in China.
·Macromolecular cdmo
In the field of cdmo, Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) through its two wholly-owned subsidiaries – saiwan biology and SPL, jointly operate the fast-growing cdmo business. At the same time, with the help of saiwan’s profound experience of nearly half a century, it has developed and manufactured macromolecular drugs based on innovative biotherapy, and supported the clinical research and development of Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) innovative pipeline drugs.
Saiwan biology is specialized in the development and production of macromolecular pharmaceutical products. It has the professional knowledge and R & D and production capacity of mammalian cell culture, microbial fermentation, cell and gene therapy (viral and non viral vectors) and mRNA biological products. Since its establishment, it has developed about 200 different molecular structures and has a good record of timely and successful delivery.
SPL provides services related to the development and production of macromolecular pharmaceutical products extracted from animals and plants, such as pancreatic enzymes, heparin and heparin analogues. SPL has long-term business experience in developing natural drugs and has core competence in developing complex and scalable processes to extract, separate and purify natural drugs. The company provides cdmo services to dozens of new drug development enterprises, including many of the world’s top ten pharmaceutical enterprises, supports more than 300 clinical trials, and has high customer loyalty and industry referral rate.
·Drug innovation
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) starts with the unmet clinical needs of patients, focuses on the investment, exploration, development and commercialization of differentiated innovative drugs, and has a highly innovative clinical pipeline.
Up to now, the company is independently developing a candidate drug in the field of cancer currently in the preclinical stage. In addition, through industrial investment and equity investment, the company holds more than 20 first in class new drug varieties of the same kind under different equity degrees, covering more than 30 indications; Five indications have entered the global phase III clinical stage and 18 indications have entered the global phase II clinical stage; Among all varieties held, Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) directly or indirectly owns all the interests in Greater China region (including Hong Kong, Macao and Taiwan) of 10 varieties through holding joint venture subsidiaries. At present, the development of three drugs is in phase III clinical stage in the world. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years □ yes √ no
Unit: Yuan
Year end 2021 year end 2020 year end increase or decrease over the previous year year end 2019 year end
Total assets 19108175266781902589465411 0.43% 1524220540345
Net assets attributable to shareholders of listed companies 11411354455881156939253092 – 1.37% 734701076112
20212020 year-on-year increase or decrease 2019
Operating income 636517748341533207487527 19.38% 462465361642
Net profit attributable to shareholders of listed companies 24078757867102420983993 – 76.49% 105935 Orient Group Incorporation(600811)
Net profit attributable to shareholders of listed companies after deducting non recurring profit and loss of 901120592759200748248 – 84.78% 44598405172
Net cash flow from operating activities -6629319803728362507 – 117.78% – 227 Shaanxi Beiyuan Chemical Industry Group Co.Ltd(601568) 17
Basic earnings per share (yuan / share) 0.1641 0.7568 – 78.32% 0.8494
Diluted earnings per share of RMB -32.68/840.68
Weighted average return on net assets: 2.09%, 11.23% – 9.14%, 15.77%
(2) Quarterly main accounting data
Unit: Yuan
First quarter second quarter third quarter fourth quarter
Operating income 12678767964518456 Guangdong Hotata Technology Group Co.Ltd(603848) 715177452202417338958185
Net profit attributable to shareholders of listed company 143483266731946748055312334758191 – 22071807550
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses of 114511999791702876376012327770312 – 31796528124
Net cash flow from operating activities 41980668716 -15418309535 -14290104301 -12935186860
Whether the above financial indicators or their total amount are significantly different from the financial indicators related to the quarterly report and semi annual report disclosed by the company □ yes √ No 4. Share capital and shareholders (1) number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of the top 10 shareholders
Unit: shares
The disclosure date of the annual report is before the disclosure date of the annual report of voting rights at the end of the reporting period
At the end of the reporting period, the voting rights of preferred shares of common 29871 restored at the end of the month before common 31671 were restored at the end of the month
Total number of preferred shareholders with 0 shares
Total number of shareholders
